Harmony Biosciences (HRMY) announced dosing of the first participant in a Phase 1 clinical trial of BP1.15205, an investigational orexin 2 receptor agonist being developed for the treatment of narcolepsy, idiopathic hypersomnia and other central disorders of hypersomnolence. The Phase 1 clinical trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of BP1.15205 after single and multiple ascending doses in healthy volunteers and sleep-deprived healthy subjects. Topline data are expected in 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences management to meet with Oppenheimer
- Harmony Biosciences price target raised to $39 from $36 at Mizuho
- Harmony Biosciences Holdings: Strong Q3 Performance and Growth Potential Justify Buy Rating
- Harmony Biosciences Reports Strong Q3 2025 Results
- Harmony Biosciences Q3 Earnings Call Highlights Robust Growth